Clinical Trial Update: Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) [Phase 1]

View source ↗

Summary

This update reports safety data and preliminary efficacy signals from a Phase 1 study of DCC-2036 in patients with Philadelphia chromosome–positive chronic myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DCC-2036

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: Chronic Myeloid Leukemia | Phase 1 | Status: COMPLETED